Federation Des Caisses Desjardins Du Quebec Inovio Pharmaceuticals, Inc. Transaction History

Federation Des Caisses Desjardins Du Quebec

$18.9 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 14, 2024	SELL	$0.35 - $0.53 $595 - $901	-1,700 Reduced 17.0%	8,300 $4.23 Million
Q3 2023 Aug 14, 2024	SELL	$0.38 - $0.58 $380 - $580	-1,000 Reduced 9.09%	10,000 $3.89 Million
Q2 2023 Aug 14, 2024	BUY	$0.39 - $0.94 $390 - $940	1,000 Added 10.0%	11,000 $4.92 Million
Q1 2023 Aug 14, 2024	BUY	$0.79 - $1.91 $395 - $955	500 Added 5.26%	10,000 $8.2 Million
Q4 2022 Aug 14, 2024	SELL	$1.41 - $2.5 $705 - $1,250	-500 Reduced 5.0%	9,500 $14.8 Million
Q2 2022 Aug 14, 2024	SELL	$1.44 - $3.98 $144 - $398	-100 Reduced 0.99%	10,000 $17.3 Million
Q1 2022 Aug 14, 2024	BUY	$2.97 - $5.2 $29,997 - $52,520	10,100 New	10,100 $36.3 Million
Q4 2021 Aug 30, 2024	SELL	$4.99 - $7.46 $1,996 - $2,984	-400 Reduced 3.81%	10,100 $50.4 Million
Q2 2021 Aug 30, 2024	BUY	$6.23 - $10.03 $65,415 - $105,315	10,500 New	10,500 $97.3 Million
Q1 2021 Aug 30, 2024	SELL	$8.81 - $16.96 $133,031 - $256,096	-15,100 Reduced 58.98%	10,500 $97.4 Million
Q4 2020 Aug 30, 2024	SELL	$8.5 - $12.85 $13,600 - $20,560	-1,600 Reduced 5.88%	25,600 $227 Million
Q3 2020 Aug 30, 2024	BUY	$9.57 - $27.05 $174,174 - $492,310	18,200 Added 202.22%	27,200 $316 Million
Q2 2020 Aug 30, 2024	SELL	$7.14 - $31.69 $9,282 - $41,197	-1,300 Reduced 12.62%	9,000 $243 Million
Q1 2020 Aug 30, 2024	BUY	$2.98 - $14.09 $21,903 - $103,561	7,350 Added 249.15%	10,300 $76.6 Million
Q4 2018 Aug 30, 2024	BUY	$3.89 - $6.11 $11,475 - $18,024	2,950 New	2,950 $11.8 Million
Q2 2017 Aug 30, 2024	BUY	N/A	2,950	2,950 $23.1 Million

Others Institutions Holding INO

# of Institutions

Shares Held

281K

Call Options Held

Put Options Held

View Full List

About INOVIO PHARMACEUTICALS, INC.

Ticker INO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 249,400,000
Market Cap $459M
Description
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA se...

More about INO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account